Epidemiology of whooping cough & typing of Bordetella pertussis.
暂无分享,去创建一个
[1] J. Brisson,et al. Comparison of lipopolysaccharide structures of Bordetella pertussis clinical isolates from pre- and post-vaccine era. , 2013, Carbohydrate research.
[2] I. Martin,et al. Genetic analysis of Bordetella pertussis in Ontario, Canada reveals one predominant clone. , 2013, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[3] Hugues Bedouelle,et al. In-vitro and in-vivo analysis of the production of the Bordetella type three secretion system effector A in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. , 2013, Microbes and infection.
[4] N. Guiso,et al. Virulence of Pertactin-NegativeBordetella pertussisIsolates from Infants, France , 2013 .
[5] A. Evangelista,et al. Pertactin-negative variants of Bordetella pertussis in the United States. , 2013, The New England journal of medicine.
[6] K. Spicer,et al. Epidemiologic and laboratory features of a large outbreak of pertussis-like illnesses associated with cocirculating Bordetella holmesii and Bordetella pertussis--Ohio, 2010-2011. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] F. Mooi,et al. Pulsed-Field Gel Electrophoresis Analysis of Bordetella pertussis Isolates Circulating in Europe from 1998 to 2009 , 2012, Journal of Clinical Microbiology.
[8] T. Nicholson,et al. Identification of a CO2 Responsive Regulon in Bordetella , 2012, PloS one.
[9] F. Mooi,et al. Small Mutations in Bordetella pertussis Are Associated with Selective Sweeps , 2012, PloS one.
[10] G. Dore,et al. Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[11] J. Mertsola,et al. Appearance of Bordetella pertussis Strains Not Expressing the Vaccine Antigen Pertactin in Finland , 2012, Clinical and Vaccine Immunology.
[12] Robert S Ware,et al. Number and order of whole cell pertussis vaccines in infancy and disease protection. , 2012, JAMA.
[13] D. Hinton,et al. The Bordetella pertussis model of exquisite gene control by the global transcription factor BvgA. , 2012, Microbiology.
[14] D. Hozbor,et al. Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America , 2012, Journal of applied microbiology.
[15] M. Peeters,et al. Surveillance of transmitted drug-resistant HIV among young pregnant women in Ouagadougou, Burkina Faso. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] Y. Arakawa,et al. Prevalence and Genetic Characterization of Pertactin-Deficient Bordetella pertussis in Japan , 2012, PloS one.
[17] C. Locht,et al. The ins and outs of pertussis toxin , 2011, The FEBS journal.
[18] S. Guillot,et al. Significant Finding of Bordetella holmesii DNA in Nasopharyngeal Samples from French Patients with Suspected Pertussis , 2011, Journal of Clinical Microbiology.
[19] P. van Damme,et al. Rationale for pertussis booster vaccination throughout life in Europe. , 2011, The Lancet. Infectious diseases.
[20] Who Publication. Pertussis vaccines: WHO position paper--recommendations. , 2011, Vaccine.
[21] A. Abe,et al. Differential Expression of Type III Effector BteA Protein Due to IS481 Insertion in Bordetella pertussis , 2011, PloS one.
[22] N. Guiso,et al. Monitoring of Bordetella isolates circulating in Saint Petersburg, Russia between 2001 and 2009. , 2010, Research in microbiology.
[23] N. Carbonetti,et al. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. , 2010, Future microbiology.
[24] T. Kallonen,et al. Bordetella pertussis vaccine strains and circulating isolates in Serbia. , 2010, Vaccine.
[25] U. Heininger. Update on pertussis in children , 2010, Expert review of anti-infective therapy.
[26] N. Guiso. Bordetella pertussis and pertussis vaccines. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] G. Dore,et al. First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. , 2009, Vaccine.
[28] F. Mooi,et al. Analysis of Swedish Bordetella pertussis isolates with three typing methods: characterization of an epidemic lineage. , 2009, Journal of microbiological methods.
[29] F. Mooi,et al. Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence , 2009, Emerging infectious diseases.
[30] V. Chenal-Francisque,et al. Genomic analysis of the adenylate cyclase-hemolysin C-terminal region of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. , 2009, Research in microbiology.
[31] N. Guiso,et al. Genomic analysis and comparison of Bordetella pertussis isolates circulating in low and high vaccine coverage areas. , 2008, Microbes and infection.
[32] J. Mertsola,et al. Bordetella pertussis isolates in Finland: Serotype and fimbrial expression , 2008, BMC Microbiology.
[33] B. Soubeyrand,et al. Pertussis Surveillance in Private Pediatric Practices, France, 2002–2006 , 2008, Emerging infectious diseases.
[34] V. Caro,et al. Genomic Content of Bordetella pertussis Clinical Isolates Circulating in Areas of Intensive Children Vaccination , 2008, PloS one.
[35] V. Caro,et al. Is the Sequenced Bordetella pertussis Strain Tohama I Representative of the Species? , 2008, Journal of Clinical Microbiology.
[36] N. Guiso,et al. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. , 2007, Vaccine.
[37] C. Locht,et al. Temporal analysis of French Bordetella pertussis isolates by comparative whole-genome hybridization. , 2006, Microbes and infection.
[38] J. Mertsola,et al. Bordetella pertussis, Finland and France , 2006, Emerging infectious diseases.
[39] F. Mooi,et al. Bordetella pertussis, the Causative Agent of Whooping Cough, Evolved from a Distinct, Human-Associated Lineage of B. bronchiseptica , 2005, PLoS pathogens.
[40] N. Guiso,et al. Characterization of Adenylate Cyclase-Hemolysin Gene Duplication in a Bordetella pertussis Isolate , 2004, Infection and Immunity.
[41] N. Fry,et al. Sequence variation and conservation in virulence-related genes of Bordetella pertussis isolates from the UK. , 2004, Journal of medical microbiology.
[42] B. Barrell,et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica , 2003, Nature Genetics.
[43] E. Hewlett,et al. Mechanism of association of adenylate cyclase toxin with the surface of Bordetella pertussis: a role for toxin–filamentous haemagglutinin interaction , 2002, Molecular microbiology.
[44] F. Mooi,et al. Multilocus Sequence Typing of Bordetella pertussis Based on Surface Protein Genes , 2002, Journal of Clinical Microbiology.
[45] C. Boursaux-Eude,et al. Polymorphism of Bordetella pertussisIsolates Circulating for the Last 10 Years in France, Where a Single Effective Whole-Cell Vaccine Has Been Used for More than 30 Years , 2001, Journal of Clinical Microbiology.
[46] H. Hallander,et al. Fimbrial Typing of Bordetella pertussis Isolates: Agglutination with Polyclonal and Monoclonal Antisera , 2001, Journal of Clinical Microbiology.
[47] J. Brisson,et al. Structure of the Bordetella pertussis 1414 endotoxin , 2000, FEBS letters.
[48] F. Mooi,et al. Epidemiological Typing of Bordetella pertussis Isolates: Recommendations for a Standard Methodology , 2000, European Journal of Clinical Microbiology and Infectious Diseases.
[49] F. Mooi,et al. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. , 1999, Microbiology.
[50] J. Desenclos,et al. Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. , 1998, The Pediatric infectious disease journal.
[51] S. Mboup,et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. , 1997, Vaccine.
[52] F. Mooi,et al. Dynamics of the population structure of Bordetella pertussis as measured by IS1002-associated RFLP: comparison of pre- and post-vaccination strains and global distribution. , 1996, Microbiology.
[53] P. François,et al. Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France , 1996, Clinical and diagnostic laboratory immunology.
[54] R. Matthews,et al. Genetic relatedness of Bordetella species as determined by macrorestriction digests resolved by pulsed-field gel electrophoresis. , 1993, International journal of systematic bacteriology.
[55] M. López. [The genus Bordetella. By Manuel Moreno López, 1952]. , 1990 .
[56] S. Toma,et al. Bordetella pertussis serotypes in Canada. , 1978, Canadian Medical Association journal.
[57] J. Nelson. The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. , 1978, American journal of diseases of children.
[58] D. Miller,et al. The serotypes of Bordetella pertussis isolated in Great Britain between 1941 and 1968 and a comparison with the serotypes observed in other countries over this period , 1976, Journal of Hygiene.
[59] B. Lacey. Antigenic modulation of Bordetella pertussis , 1960, Journal of Hygiene.
[60] Marvin Israel. Whooping Cough. By Joseph H. Lapin, B. Chem., M.D. , 1943 .
[61] P. H. Leslie,et al. The Phases of Haemophilus pertussis , 1931, Journal of Hygiene.
[62] S. Guillot,et al. Insertion sequences shared by Bordetella species and implications for the biological diagnosis of pertussis syndrome , 2012, European Journal of Clinical Microbiology & Infectious Diseases.